Bausch Health Companies Azioni (NYSE: BHC)

Ultime notizie per Bausch Health Companies (NYSE:BHC) Azioni

Bausch Health Companies

Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Cos

Bausch Health Companies Inc. Common Stock

Bausch Health Companies Inc

BillionHappiness

BENCHMARK HLDGS PLC by Benchmark Hldgs PLC

Benchmark Holdings PLC

BAUSCH HEALTH COMPANIES ORD

Truist Securities analyst Miller Jump reiterates JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) with a Buy and raises the price target from $33 to $35.

News

Price Target

Reiteration

Analyst Ratings

FROG

Truist Securities Reiterates Buy on JFrog, Raises Price Target to $35

WIIM

Genpact shares are trading higher after the company reported better-than-expected Q3 financial results. Also, Baird raised its price target on the stock from $44 to $48.

Benchmark analyst Mark Palmer maintains Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) with a Buy and raises the price target from $20 to $21.

LSPD

Benchmark Maintains Buy on Lightspeed Commerce, Raises Price Target to $21

Truist Securities analyst Terry Tillman reiterates HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and raises the price target from $600 to $750.

HUBS

Truist Securities Reiterates Buy on HubSpot, Raises Price Target to $750

AVPT

AvePoint shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 and Q4 sales guidance.

CoreCivic shares are trading higher after Jones Trading upgraded the stock from Hold to Buy.

Truist Securities analyst Mark Hughes maintains HCI Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCI#NYSE">HCI</a>) with a Buy and raises the price target from $140 to $145.

Truist Securities Maintains Buy on HCI Group, Raises Price Target to $145

Scotiabank analyst Nick Altmann maintains OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Sector Outperform and raises the price target from $34 to $35.

Scotiabank Maintains Sector Outperform on OneStream, Raises Price Target to $35

Fluor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) shares plummeted after the company reported third-quarter results <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41838628/fluor-reports-third-quarter-2024-results" rel="noreferrer noopener">below street expectations.</a>
FLR&#8217;s revenue grew 3.3% year over year to $4.09 billion, missing the consensus of $4.738 billion. Adjusted EPS declined to 51 cents from $1.02 a year ago, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missing the consensus of 76 cents.</a>
Sales by segment: Energy Solutions $1.428 billion (-8.1% YoY), Urban Solutions $1.93 billion (+34.9% YoY), Mission Solutions $635 million (-3.1% YoY) and Others $100 million (-69.1% YoY).
FLR recorded a total segment profit of $117 million, compared to $276 million a year ago. The margin contracted 411 bps to 2.9%.
The company reported net earnings from core operations of $60 million, down from $158 million a year ago.
The total new awards were $2.69 billion compared to $4.976 billion a year ago. New awards related to projects located outside of the U.S. totaled 68%.
Consolidated backlog surged 20.4% year-over-year to $31.32 billion, with 80% of projects being reimbursable.
Adjusted EBITDA declined 42.6% year-over-year to $124 million, and the margin declined 242 bps to 3%.
At the end of the quarter, Fluor&#8217;s cash and marketable securities were $2.9 billion, excluding amounts held by NuScale. Operating cash flow for the nine months ended September amounted to $501 million.
Buyback: Fluor&#8217;s Board of Directors approved expanding its share repurchase program to 30.5 million shares as part of its capital allocation strategy.
Fluor announced it will deconsolidate NuScale starting in the&nbsp;fourth quarter, resulting in a $1.6 billion gain. Also, the company expects to complete the sale of Stork&#8217;s U.K. operations as early as the&nbsp;first quarter&nbsp;of 2025, pending regulatory approval.
2024 Outlook: FLR tightened its adjusted EPS outlook to $2.55 to $2.75 <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">(prior $2.50 to $3.00) versus the $2.89 consensus.</a>
The company lowered its adjusted&nbsp;EBITDA outlook to $525 million &#8211; $575 million (prior $625 million &#8211; $675 million) and increased cash flow guidance to ~$700 million.
Price Action: FLR shares are trading lower by 16.4% at $49.25 at the last check Friday.

Earnings

Equities

Guidance

Movers

Engineering & Construction Company Fluor Misses Big On Q3 Earnings And Revises 2024 Guidance As Project Delays Bite

Online cannabis discovery marketplace Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) announced its financial results Thursday for the third quarter ended Sept. 30, 2024, with revenue of $8.4 million down from $10.6 million in the Q3 2023. Leafly attributes the year-over-year revenue decline to fewer retail accounts and reduced spending by customers due to budget constraints.
&#8220;With two consecutive quarters of positive adjusted EBITDA and a retail business that has largely reached a point of stabilization, we're poised to capitalize on the growth opportunities ahead," stated Leafly CEO Yoko Miyashita. "We'll continue our laser focus on building a lean and efficient business operation to capitalize on the stabilizing revenue trajectory of the retail business."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41791053/terrascend-expands-footprint-despite-q3-losses-can-a-move-to-ohio-turn-the-tide">TerrAscend Expands Footprint Despite Q3 Losses, Can A Move To Ohio Turn The Tide?</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Third Quarter Financial Highlights</h2>
<ul>
<li>Gross margin was 89%, consistent with gross margin reported in Q3 2023.</li>
<li>Total operating expenses was $8.0 million, a 27% reduction from $10.9 million in Q3 2023, reflecting operational rigor and a continued focus on cost discipline.</li>
<li>Net loss was $1.1 million, compared to net loss of $2.2 million for Q3 2023.</li>
<li>Adjusted EBITDA was $378,000 compared to an adjusted EBITDA loss of $176,000 in Q3 2023.</li>
</ul>
During the quarter, the number of retail accounts dropped 20% year-over-year to 3,554 and 1% sequentially from Q2 2024. The declines are primarily due to customers' budget constraints and Leafly's removal of non-paying customers from the platform over the last twelve months.
At the same time, the average retail accounts spending grew 8% to $695 primarily due to the removal of lower ARPA accounts from the platform, coupled with targeted price increases on Leafly products over the last 12 months.
"Our highest priority is addressing the maturity of our convertible notes, which are due in January 2025. We are actively working on resolving this issue, and remain focused on reducing cash burn and running the business efficiently. With the business on a firmer footing, we are targeting growth next year," said Leafly CFO Suresh Krishnaswamy. 
<h2 class="wp-block-heading">Price Action</h2>
Leafly shares traded 5.37% lower at $1.41 after hours on Thursday.
 Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41819542/zig-zag-rolling-papers-segment-drives-47-of-turning-point-brands-q3-sales-ceo-predicts-sustainab">Zig-Zag Rolling Papers Segment Drives 47% Of Turning Point Brands&#8217; Q3 Sales, CEO Predicts Sustainable Growth</a></li>
</ul>
Photo: Courtesy of Plateresca via Shutterstock

Cannabis

LFLY

Leafly Holdings' 20% YoY Drop In Q3 Revenue And Customer Accounts

Truist Securities analyst Bertrand Donnes maintains Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) with a Buy and raises the price target from $190 to $203.

GPOR

Truist Securities Maintains Buy on Gulfport Energy, Raises Price Target to $203

Benchmark analyst Mark Zgutowicz maintains Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) with a Buy and raises the price target from $8.5 to $9.5.

STGW

Benchmark Maintains Buy on Stagwell, Raises Price Target to $9.5

Scotiabank analyst Meny Grauman maintains Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Sector Outperform and raises the price target from C$48 to C$49.

TSX:MFC

Scotiabank Maintains Sector Outperform on Manulife Financial, Raises Price Target to C$49

Truist Securities analyst Asthika Goonewardene maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Hold and raises the price target from $83 to $97.

GILD

Truist Securities Maintains Hold on Gilead Sciences, Raises Price Target to $97

SEMR

SEMrush Holdings shares are trading lower after the company reported worse-than-expected Q3 EPS results.

ALRM

Alarm.com shares are trading higher after Goldman Sachs raised its price target on the stock from $64 to $67.

Truist Securities analyst Tobey Sommer maintains GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) with a Buy and raises the price target from $46 to $54.

Truist Securities Maintains Buy on GFL Environmental, Raises Price Target to $54

Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $39.63 million which beat the analyst consensus estimate of $38.50 million by 2.95 percent. This is a 25.00 percent decrease over sales of $52.85 million the same period last year.

VSTA

Vasta Platform Q3 Adj $(0.10) Beats $(0.13) Estimate, Sales $39.63M Beat $38.50M Estimate

FIVN

Five9 shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $35 to $46. Needham also reiterated its Buy rating.

Benchmark analyst Mark Miller maintains Nova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) with a Buy and raises the price target from $240 to $245.

NVMI

Benchmark Maintains Buy on Nova, Raises Price Target to $245

Here are the major earnings after the close today

Pre-earnings options volume in Bausch Health (BHC) is normal with calls leading puts 10:3. Implied volatility suggests the market is anticipating a...

Bausch Health options imply 10.2% move in share price post-earnings

Bausch Health Companies (TSE:BHC) has released an update. Bausch Health Companies reported a strong third quarter of 2024, achieving a 12% increase...

Bausch Health Reports Strong Growth in Q3 2024

Bausch Health Companies GAAP EPS of -$0.23 misses by $0.37, revenue of $2.51B beats by $90M

Bausch Health raises 2024 revenue guidance

Bausch Health Companies Inc. 2024 Q3 - Results - Earnings Call Presentation

Bausch Health Companies ( ($BHC) ) has realeased its Q3 earnings. Here is a breakdown of the information Bausch Health Companies presented to its i...

Bausch Health Reports Growth Amid Improved Financials

Truist Financial analyst Les Sulewski maintained a Hold rating on Bausch Health Companies (BHC – Research Report) today and set a price target of $...

Truist Financial Keeps Their Hold Rating on Bausch Health Companies (BHC)

Steve Scala, an analyst from TD Cowen, maintained the Hold rating on Bausch Health Companies (BHC – Research Report). The associated price target i...

Bausch Health Companies: Hold Rating Amid Mixed Financial Performance and Strategic Uncertainty

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly exploring a potential sale in ...

Bausch + Lomb (BLCO) Posts Impressive Revenue and Explores Potential Sale

ACGL

ACHC

AEIS

ALGT

ALTR

AMRN

AMSC

AMWL

ATEC

AXAHY

BECN

BKNG

BLCO

HOOD

HTGC

HUBG

IMAX

INVH

IRTC

JAKK

KLAC

LMND

LPLA

MATX

MSFT

PPSI

RIOT

ROOT

SBUX

SIMO

SNBR

SPOK

SPXC

SSNLF

STAA

STEM

TDOC

TENB

Legal

Press Releases

Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals

Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024

Management

Bausch Health Welcomes Two New Members to the Executive Leadership Team

Bausch Health Responds to Market Rumors

Bausch Health Announces Second Quarter 2024 Results

Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older

Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

Events

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Comments

Bausch Health Companies

Notizie

Ultime notizie per Bausch Health Companies (NYSE:BHC) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO